세계의 뇌경색 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Cerebral Infarction Treatment Market was valued at USD 13.4 billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 27.4 billion by 2034. This market is witnessing steady growth due to the increasing prevalence of stroke and rising awareness about the importance of timely treatment. Cerebral infarction, a form of stroke caused by an interruption in blood flow to the brain, leads to tissue damage and, if left untreated, can result in long-term disability or death. This interruption is typically caused by a blood clot blocking a vessel, depriving brain cells of oxygen and essential nutrients. As medical infrastructure and diagnostic capabilities improve globally, earlier detection and more effective treatments are becoming available, pushing the demand for therapeutic interventions. Additionally, advances in clinical research and increased funding for neurological disorders are accelerating the development of innovative therapies and treatment options, driving market expansion. With a growing geriatric population and a surge in risk factors like hypertension and diabetes, the demand for more responsive and effective cerebral infarction treatments continues to climb. The emergence of emergency care systems and rapid-response treatment options has significantly influenced patient outcomes, thus boosting the market's long-term potential.

By drug class, the cerebral infarction treatment market is segmented into tissue plasminogen activators (tPA), anticoagulants, antiplatelets, anticonvulsants, and other drugs. The total market revenue for 2023 was USD 12.6 billion. The tPA segment alone generated USD 4.4 billion in 2024 and is expected to grow at a CAGR of 7.8% throughout the forecast period. Tissue plasminogen activators help dissolve blood clots by breaking down fibrin, a core protein involved in clot formation, thus reestablishing blood flow to the brain and minimizing oxygen loss-related damage. Administering tPA within the first few hours of symptom onset has been shown to significantly improve recovery, reduce disability, and enhance overall treatment outcomes. These therapies are now considered essential in emergency stroke protocols due to their efficiency and ability to reduce long-term neurological impairment.

When categorized by type, the market is divided into ischemic stroke and hemorrhagic stroke. Ischemic stroke dominated the segment with a revenue of USD 10.5 billion in 2024, accounting for 78.5% of the total market. This dominance is attributed to the high global incidence of ischemic strokes compared to other types. Treatments like thrombolysis and thrombectomy are increasingly adopted to restore blood flow and limit neurological damage. Medications such as antiplatelets (aspirin, clopidogrel) and anticoagulants (including dabigatran and rivaroxaban) are routinely prescribed to prevent recurrence, particularly in patients with underlying cardiovascular risk factors. Early treatment greatly improves motor, speech, and cognitive recovery, which helps reduce the chances of long-term disability, thereby supporting market growth.

Based on the route of administration, the market is segmented into oral and injectable therapies. Injectables accounted for a significant 64.6% share of the total market in 2024. These therapies are favored in emergency settings due to their fast action and precise dosage control, essential for acute stroke treatment. Intravenous administration allows healthcare providers to quickly deliver clot-dissolving medications directly into the bloodstream, providing rapid therapeutic effects when time is critical. Their suitability in ambulances and hospital environments enhances their value in modern stroke care systems, making injectables a cornerstone of immediate intervention strategies.

In terms of distribution channels, hospital pharmacies held the largest revenue share in 2024, generating USD 6.5 billion. These settings offer direct access to life-saving drugs under medical supervision, particularly important for treatments requiring urgent attention. Hospital pharmacies also play a key role in patient education, offering guidance on medication types, administration methods, and side effects. Their integration with healthcare teams ensures better adherence to treatment plans, improving patient outcomes. Additionally, services such as medication management and support programs foster long-term treatment success.

Regionally, North America emerged as a leading market, with a revenue of USD 5.4 billion in 2024 and a projected rise to USD 10.9 billion by 2034. The United States was the largest contributor, with USD 4.7 billion in revenue in 2023. The region's high healthcare expenditure, advanced medical infrastructure, and increased awareness about stroke care have helped it maintain its dominant position. The growing incidence of cardiovascular conditions in this region further fuels the need for effective treatments.

Key market players-accounting for roughly 45% of the total share-include companies such as Abbott Laboratories, Boehringer Ingelheim, F. Hoffmann-La Roche, and Novo Nordisk. These companies continue to lead the market through strategic product innovations, robust distribution networks, and regulatory expertise. Partnerships with healthcare institutions and public health organizations are facilitating research efforts and improving treatment accessibility. Awareness campaigns and the growing influence of digital platforms are also encouraging more individuals to seek timely treatment, thus contributing to market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Innovation in drug development
    • 3.2.1.3 Increasing R&D for stroke therapeutics
    • 3.2.1.4 Growing number of geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects of medications
    • 3.2.2.2 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (Cost of Manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (Cost to Consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Pipeline analysis
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Tissue plasminogen activators (tPA)
• 5.3 Anticoagulants
• 5.4 Antiplatelets
• 5.5 Anticonvulsants
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Ischemic stroke
• 6.3 Hemorrhagic stroke

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Amgen
• 10.3 Amneal Pharmaceuticals
• 10.4 AstraZeneca
• 10.5 Boehringer Ingelheim
• 10.6 Bayer
• 10.7 Biogen
• 10.8 Daiichi Sankyo Company
• 10.9 F. Hoffmann-La Roche
• 10.10 Merck & Co.
• 10.11 Novartis
• 10.12 Novo Nordisk
• 10.13 Otsuka Holdings
• 10.14 Pfizer
• 10.15 Sanofi